PMID- 31486514
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 16
DP  - 2019 Aug
TI  - Atorvastatin improves the cardiac function of rats after acute myocardial 
      infarction through ERK1/2 pathway.
PG  - 7120-7127
LID - 18757 [pii]
LID - 10.26355/eurrev_201908_18757 [doi]
AB  - OBJECTIVE: To study the regulatory effect of atorvastatin (ATV) on the 
      extracellular signal-regulated kinase (ERK) 1/2 pathway and explore its effect on 
      acute myocardial infarction (AMI) rats. MATERIALS AND METHODS: The rat model of 
      AMI was established, and the model rats were randomly divided into AMI group and 
      ATV-AMI group, and Sham group was also set up. At 4 weeks after successful 
      modeling, the cardiac function indexes of Sprague-Dawley (SD) rats were detected 
      via magnetic resonance imaging (MRI) and echocardiography (ECG). After the rats 
      were executed, the left ventricular weight index (LVWI) was measured, and the 
      myocardial damage was detected via hematoxylin-eosin (HE) staining and terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. 
      Moreover, the messenger ribonucleic acid (mRNA) expressions of collagen I and 
      collagen III in myocardial tissues were detected via Real Time-Polymerase Chain 
      Reaction (PCR), and the expressions of ERK1/2 pathway-related proteins in 
      myocardial tissues were detected via Western blotting. RESULTS: After 
      administration of ATV for AMI, the fractional shortening (FS%) and ejection 
      fraction (EF%) were significantly restored. Compared with that in ATV-AMI group, 
      LVWI was significantly increased in AMI group (p<0.05), indicating that ATV could 
      improve the cardiac function after AMI. The results of HE staining and TUNEL 
      staining showed that ATV-AMI group had slighter myocardial damage and 
      significantly lower apoptosis rate than AMI group, indicating that ATV could 
      reverse AMI through the ERK1/2 pathway. Besides, the mRNA expressions of collagen 
      I and collagen III were higher in AMI group and ATV-AMI group than those in Sham 
      group (p<0.05), while they were significantly lower in ATV-AMI group than those 
      in AMI group (p<0.05). The expressions of ERK1/2 pathway-related proteins were 
      also higher in AMI group and ATV-AMI group than those in Sham group (p<0.05). 
      CONCLUSIONS: ATV can significantly improve the cardiac function of SD rats after 
      AMI, whose mechanism is related to the expression of the ERK1/2 pathway.
FAU - Zeng, H-T
AU  - Zeng HT
AD  - Department of Pharmacy, Shenzhen Longgang E.N.T. Hospital, Shenzhen, China. 
      5254390@qq.com.
FAU - Zhao, M
AU  - Zhao M
FAU - Zhang, Z-X
AU  - Zhang ZX
FAU - Liu, Z-L
AU  - Liu ZL
FAU - Zhong, S-M
AU  - Zhong SM
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - A0JWA85V8F (Atorvastatin)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Animals
MH  - Atorvastatin/administration & dosage/*therapeutic use
MH  - Disease Models, Animal
MH  - Echocardiography
MH  - Heart Function Tests
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/*therapeutic use
MH  - MAP Kinase Signaling System
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Mitogen-Activated Protein Kinase 1/genetics/*metabolism
MH  - Mitogen-Activated Protein Kinase 3/genetics/*metabolism
MH  - Myocardial Infarction/diagnostic imaging/*drug therapy/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2019/09/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/09/06 06:00
PHST- 2019/09/06 06:00 [entrez]
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 18757 [pii]
AID - 10.26355/eurrev_201908_18757 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):7120-7127. doi: 
      10.26355/eurrev_201908_18757.